These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 31022686)

  • 1. Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants.
    Dowling DJ
    Immunohorizons; 2018 Jul; 2(6):185-197. PubMed ID: 31022686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
    Vasilakos JP; Tomai MA
    Expert Rev Vaccines; 2013 Jul; 12(7):809-19. PubMed ID: 23885825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination.
    Dowling DJ; Barman S; Smith AJ; Borriello F; Chaney D; Brightman SE; Melhem G; Brook B; Menon M; Soni D; Schüller S; Siram K; Nanishi E; Bazin HG; Burkhart DJ; Levy O; Evans JT
    Sci Rep; 2022 Oct; 12(1):16860. PubMed ID: 36258023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A TLR7/8 Agonist-Including DOEPC-Based Cationic Liposome Formulation Mediates Its Adjuvanticity Through the Sustained Recruitment of Highly Activated Monocytes in a Type I IFN-Independent but NF-κB-Dependent Manner.
    Auderset F; Belnoue E; Mastelic-Gavillet B; Lambert PH; Siegrist CA
    Front Immunol; 2020; 11():580974. PubMed ID: 33262759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-encapsulation of synthetic lipidated TLR4 and TLR7/8 agonists in the liposomal bilayer results in a rapid, synergistic enhancement of vaccine-mediated humoral immunity.
    Short KK; Miller SM; Walsh L; Cybulski V; Bazin H; Evans JT; Burkhart D
    J Control Release; 2019 Dec; 315():186-196. PubMed ID: 31654684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvants.
    Smith AJ; Li Y; Bazin HG; St-Jean JR; Larocque D; Evans JT; Baldridge JR
    Vaccine; 2016 Aug; 34(36):4304-12. PubMed ID: 27402566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques.
    Moody MA; Santra S; Vandergrift NA; Sutherland LL; Gurley TC; Drinker MS; Allen AA; Xia SM; Meyerhoff RR; Parks R; Lloyd KE; Easterhoff D; Alam SM; Liao HX; Ward BM; Ferrari G; Montefiori DC; Tomaras GD; Seder RA; Letvin NL; Haynes BF
    J Virol; 2014 Mar; 88(6):3329-39. PubMed ID: 24390332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly(d,l-lactide-co-glycolide) Nanoparticles as Delivery Platforms for TLR7/8 Agonist-Based Cancer Vaccine.
    Kim H; Griffith TS; Panyam J
    J Pharmacol Exp Ther; 2019 Sep; 370(3):715-724. PubMed ID: 30610006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity.
    Johnson TR; Rao S; Seder RA; Chen M; Graham BS
    Vaccine; 2009 May; 27(23):3045-52. PubMed ID: 19428918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice.
    Rostamian M; Niknam HM
    Mol Immunol; 2017 Nov; 91():202-208. PubMed ID: 28963929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants.
    Bhagchandani S; Johnson JA; Irvine DJ
    Adv Drug Deliv Rev; 2021 Aug; 175():113803. PubMed ID: 34058283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates.
    Wille-Reece U; Flynn BJ; Loré K; Koup RA; Miles AP; Saul A; Kedl RM; Mattapallil JJ; Weiss WR; Roederer M; Seder RA
    J Exp Med; 2006 May; 203(5):1249-58. PubMed ID: 16636134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists.
    Collier MA; Junkins RD; Gallovic MD; Johnson BM; Johnson MM; Macintyre AN; Sempowski GD; Bachelder EM; Ting JP; Ainslie KM
    Mol Pharm; 2018 Nov; 15(11):4933-4946. PubMed ID: 30281314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The synthesis and preliminary immunological evaluation of a dual-adjuvant SARS-CoV-2 RBD vaccine: Covalent integration of TLR7/8 and iNKT cell agonists.
    Xu Y; Yang J; Meng X; Meng S; Sun T; Ding N; Zong C
    Int J Biol Macromol; 2024 Jun; 270(Pt 1):132258. PubMed ID: 38735613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TLR-7 and -8 agonists as vaccine adjuvants.
    Tomai MA; Vasilakos JP
    Expert Rev Vaccines; 2011 Apr; 10(4):405-7. PubMed ID: 21506636
    [No Abstract]   [Full Text] [Related]  

  • 17. Conjugation of TLR7 and TLR7/8 agonists onto weak protein antigen via versatile oxime ligation for enhanced vaccine efficacy.
    Zhang RY; Wen Y; He CB; Zhou SH; Wu YH; Wang EY; Feng RR; Ding D; Du JJ; Gao XF; Guo J
    Int J Biol Macromol; 2024 Oct; 278(Pt 1):134620. PubMed ID: 39127274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN Routes.
    McKay PF; King DF; Mann JF; Barinaga G; Carter D; Shattock RJ
    PLoS One; 2016; 11(2):e0148984. PubMed ID: 26862758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica.
    Abhyankar MM; Noor Z; Tomai MA; Elvecrog J; Fox CB; Petri WA
    Vaccine; 2017 Feb; 35(6):916-922. PubMed ID: 28089548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice.
    Zhang WW; Matlashewski G
    Infect Immun; 2008 Aug; 76(8):3777-83. PubMed ID: 18474642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.